We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Kate
Charnley
kate.charnley@nhs.net
Prof
Fiona
Gilbert
fjg28@cam.ac.uk
Study
Team
braid@medschl.cam.ac.uk
Johanna
Field-Rayner
jlb1004@medschl.cam.ac.uk
Nicholas
Payne
np520@medschl.cam.ac.uk
Malignant neoplasm of breast
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
BRAID is a randomised, multi-centre study assessing the impact of supplementary imaging in the detection of breast cancer in women participating in the UK national breast screening programme who have dense breast parenchyma.
Breast density, a measure of the amount of fibro-glandular tissue, is one of the strongest knows risk factors for breast cancer, the 10% of women with extremely dense breasts are at a 4-fold increased breast cancer risk compared to women with ‘fatty’ breasts and high breast density is associated with reduced sensitivity of mammography meaning that women with dense breasts have an increased probability of developing an interval cancer (cancer being detected between screening rounds) and of cancer being detected at a later stage.
This trial aims to answer a timely question about how best to screen women with dense breasts for breast cancer. Breast cancer screening reduces breast cancer specific mortality by 20%, however only 53% of the cancers being detected are small (< 15mm).The current national breast screening programme (NHS BSP) offers all women aged 50-70 screening with 3-yearly mammograms. It aims to reduce breast cancer mortality by detecting small cancers thereby reducing the number of late stage diagnoses.
BRAID will randomise women whose recent screening mammogram shows that they have dense breasts to either standard of care (no supplementary imaging) or supplementary imaging with abbreviated MRI (ABB-MRI), automated whole breast ultrasound (ABUS) or contrast enhanced spectral mammography (CESM). All of these imaging techniques have been shows to be more sensitive at detecting cancers within fibro-glandular tissue and our hypothesis is that more cancers will be detected at an earlier stage with the addition of supplemental imaging.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Interventional type: Imaging;
You can take part if:
You may not be able to take part if:
Part A exclusion criteria The participant may not enter the study if ANY of the following apply: • Known BRCA carrier or > = 50% risk of being a carrier • Unable to give informed consent • Breast implant(s) • Current participation in another interventional breast screening trial (Including but not limited to MyPeBS) • Pregnant or breast feeding Part B Exclusion Criteria The participant may not enter the study if ANY of the following apply: • Known BRCA carrier or > = 50% risk of being a carrier • Unable to give informed consent • Breast implant(s) • Unable to be followed-up for the study duration • Current participation in another interventional breast screening trial (Including but not limited to MyPeBS) • Pregnant or breast feeding
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Prof
Fiona
Gilbert
fjg28@cam.ac.uk
Kate
Charnley
kate.charnley@nhs.net
Study
Team
braid@medschl.cam.ac.uk
Johanna
Field-Rayner
jlb1004@medschl.cam.ac.uk
Nicholas
Payne
np520@medschl.cam.ac.uk
The study is sponsored by CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST and funded by Bayer Pharma AG; CANCER RESEARCH UK; GE HEALTHCARE LIMITED; .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 41224
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
